Replies to post #250494 on Biotech Values

[SurgeGuy2.0]

Looks like another SCAM!!!!!!

[DewDiligence]

EFTR—(-82%)—reports disastrous phase-2 data for Tomivosertib as addend to Keytruda in first-line NSCLC:

https://finance.yahoo.com/news/effector-therapeutics-announces-topline-results-123000557.html

The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold… Overall survival results remain immature, however no trend favoring tomivosertib was observed.

There were 67% Grade 3 or higher treatment emergent adverse events in the tomivosertib plus pembrolizumab arm versus 37% in the placebo plus pembrolizumab arm.